Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

(MedPage Today) — CHICAGO — Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to significantly longer disease-free survival (DFS) as compared with observation, a randomized trial showed.
DFS…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115810

Author :

Publish date : 2025-05-31 12:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

The Covid Inquiry Podcast: ‘I wasn’t the decision maker’

Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Related Posts

Government turns to TikTokers to advise on cosmetic surgery abroad

New Guideline Puts Some at the Front of the Line for GLP-1, SGLT2 Drugs

Electroconvulsive Therapy Patients Often Not Fully Informed of Risks, Study Suggests

Weight Loss Before Military Training May Cut Injury Risk

BP Meds Should Begin Promptly, New ACC/AHA Guidelines Say

Are Wearable Health Trackers Really All That? Yes and No, Doctors Say

Government turns to TikTokers to advise on cosmetic surgery abroad

New Guideline Puts Some at the Front of the Line for GLP-1, SGLT2 Drugs

Electroconvulsive Therapy Patients Often Not Fully Informed of Risks, Study Suggests

Weight Loss Before Military Training May Cut Injury Risk

BP Meds Should Begin Promptly, New ACC/AHA Guidelines Say

Are Wearable Health Trackers Really All That? Yes and No, Doctors Say

RFK Jr. Revives Dormant Vaccine Safety Task Force

Mousse Sunscreen Makers Get Warning From FDA

Categories

Archives